阿坎酸钙(Acamprosate Calcium) - 药物靶点：NMDA receptor_在研适应症：酗酒_专利_临床

概要

基本信息

药物类型

小分子化药

别名

3-Acetamido-1-propanesulfonic acid、Acamprosate、Acamprosate calcium (JAN/USAN)

+ [12]

靶点

NMDA receptor

作用方式

拮抗剂

作用机制

NMDA receptor拮抗剂(谷氨酸[NMDA]受体复合体拮抗剂)

治疗领域

其他疾病

在研适应症

酗酒

非在研适应症

暴食症甲基苯丙胺依赖精神分裂症+ [3]

原研机构-

在研机构

Nippon Shinyaku Co., Ltd.

非在研机构

Synchroneuron, Inc.Forest Laboratories, Inc.

Forest Laboratories LLC

权益机构

Forest Laboratories LLC

Merck KGaA

最高研发阶段批准上市

首次获批日期

美国 (2004-07-29),

酗酒

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C5H11CaNO4S

InChIKeyFQYZCUOYXXIDPF-UHFFFAOYSA-N

CAS号77337-73-6

关联

51

项与阿坎酸钙相关的临床试验

NCT07060638

/ Not yet recruiting临床2期IIT

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

This is a multicenter, randomized, double-blinded, placebo-controlled trial focused on the treatment of severe alcohol-associated hepatitis (sAH) and alcohol use disorder (AUD).
The primary purpose of the study is to determine whether subjects receiving sAH therapy in addition to AUD treatments will have better alcohol and liver-related outcomes at 6 months compared to sAH therapy plus usual care for AUD. Patients assigned to the AUD treatment will receive Acamprosate and counseling whereas those assigned to AUD standard care will receive brief advice and referral to a 12-step program.
The secondary purpose of the study is to determine if F-652 is safe and effective in treating sAH when compared to prednisone. Subjects will receive F-652 on days 1 and 7 or prednisone for 28 days. Outcomes will be measured by overall survival at 90 days.

开始日期2025-08-01

申办/合作机构

Indiana University

[+1]

NCT06269627

/ Recruiting临床4期IIT

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

Background:
Chronic heavy drinking can cause alcohol use disorder (AUD). AUD changes how the brain works. People with AUD may drink compulsively or feel like they cannot control their alcohol use. Acamprosate is an FDA-approved drug that reduces anxiety and craving in some, but not all, people with AUD.
Objective:
To learn more about how acamprosate affects brain function in people with AUD.
Eligibility:
People aged 21 to 65 years with moderate to severe AUD.
Design:
Participants will stay in the clinic for 21 days after a detoxification period of approximately 7 days.
Acamprosate is a capsule taken by mouth. Half of participants will take this drug 3 times a day with meals. The other half will take a placebo. The placebo looks like the study drug but does not contain any medicine. Participants will not know which capsules they are taking.
Participants will have a procedure called electroencephalography (EEG): A gel will be applied to certain locations on their scalp, and a snug cap will be placed on their head. The cap has sensors with wires. The sensors detect electrical activity in the brain. Participants will lie still and perform 2 tasks: they will look at different shapes and press a button when they see a specific one; and they will listen to tones and press dedicated buttons when they hear the corresponding tones.
Participants will have 2 EEGs: 1 on day 2 and 1 on day 23 of their study participation. They may opt to have up to 4 more EEG studies (one on day 13 and one on each of the three follow-up visits) and 2 sleep studies, in which they would have sensors attached to their scalp while they sleep.
Participants may have up to three follow-up visits for 6 months.

开始日期2025-05-07

申办/合作机构

National Institute on Alcohol Abuse & Alcoholism

CTRI/2024/07/069763

/ Not yet recruiting临床4期IIT

The comparative effectiveness of acamprosate, naltrexone, and baclofen in alcohol dependence syndrome A randomized open-label trial - NIL

开始日期2024-07-11

申办/合作机构-

100 项与阿坎酸钙相关的临床结果

登录后查看更多信息

100 项与阿坎酸钙相关的转化医学

登录后查看更多信息

100 项与阿坎酸钙相关的专利（医药）

登录后查看更多信息

1,131

项与阿坎酸钙相关的文献（医药）

2025-08-01·JOURNAL OF HAZARDOUS MATERIALS

Assessing the chemical burden of the North-East Atlantic ecosystem through targeted and untargeted HRMS-based approaches

Article

作者: Berbee, Rob ; von der Ohe, Peter ; Munch Chistensen, Anne ; Koschorreck, Jan ; Larsen, Martin Mørk ; Mil-Homens, Mário ; Pirntke, Ulrike ; Vasilatos, Konstantinos ; Soerensen, Anne L ; McHugh, Brendan ; Näslund, Johan ; Hjermann, Dag Øystein ; Parmentier, Koen ; Power, Andrew ; Athanasopoulou, Antonia ; Thomaidis, Nikolaos S ; Kammann, Ulrike ; Mauffret, Aourell ; Webster, Lynda ; Wilson, Simon ; Oliveira, Susana Galante ; Alygizakis, Nikiforos ; Burgeot, Thierry ; Oswald, Peter ; Gustafsson, Johan ; Gkotsis, Georgios ; Kirchgeorg, Torben ; Slobodnik, Jaroslav ; Viñas, Lucia ; Campos, Alejandro Iglesias ; Van der Stap, Irene ; Barber, Jonathan L ; Nika, Maria-Christina

Human activities have introduced significant amounts of anthropogenic chemicals into marine ecosystems, posing threats to aquatic biodiversity and human health. Although, traditional marine monitoring focus primarily on legacy pollutants, the presence and potential risks associated with complex emerging chemical mixtures should not be neglected. In the context of the present study organized via OSPAR Commission and supported by NORMAN network, 52 marine samples were gathered from North-East Atlantic Ocean. State-of-the-art HRMS-based analytical workflows were employed to identify their chemical fingerprint. 132 organic pollutants were identified through wide-scope target screening of more than 2,400 environmentally relevant organic pollutants. The HRMS data were digitally stored in NORMAN DSFP and 134 additional chemicals were tentatively identified through suspect screening of more than 65,000 chemicals. The list included legacy pollutants, along with emerging pollutants, their metabolites and transformation products. A simplified environmental risk assessment was conducted, aiming to prioritize substances based on their potential risks to the marine ecosystem. This study provides a valuable snapshot of the marine pollution, offering insights into chemical occurrence and risks. The findings can support marine scientists, environmental managers and policymakers in identifying pollutant sources, understanding their impacts, and informing regulatory measures to mitigate threats to marine ecosystems.

2025-08-01·ACTA PSYCHIATRICA SCANDINAVICA

Pharmacological Treatments in Alcohol Use Disorder and Risk of Alcohol‐Related Hospitalizations: A Register Study

Article

作者: Hällgren, Jonas ; Franck, Johan ; Bach, Patrick ; Widing, Härje ; Westman, Jeanette ; Gissler, Mika

ABSTRACT:

Objectives:

Despite the high prevalence of alcohol use disorder (AUD), only a minority of patients receive recommended pharmacological treatments, possibly owing to uncertainty about the real‐world effectiveness of these medications. Here, we analyzed nationwide, register‐based data to investigate the association between approved AUD medications (naltrexone, acamprosate, disulfiram, and nalmefene) and the risk of alcohol‐related hospitalizations among individuals with AUD.

Methods:

People aged 18–64 with a registered first‐time diagnosis of AUD between 2009 and 2019 (N = 93,727) were identified from the Swedish National Patient Register. Cox regression models were used to analyze the association between AUD medication exposure and the risk of alcohol‐related hospitalizations.

Results:

Exposure to naltrexone (hazard ratio [HR] = 0.80; 95% confidence interval [CI] = 0.73–0.87) or disulfiram (HR = 0.83, 95% CI = 0.79–0.88) as monotherapy, or a combination of naltrexone/disulfiram (HR = 0.68, 95% CI = 0.49–0.96), or disulfiram/acamprosate (HR = 0.57 95% CI = 0.44–0.74) was significantly associated with a lower risk of alcohol‐related hospitalizations compared to periods without exposure to any of these medications. In contrast, no significant associations were observed for acamprosate, nalmefene, or the combination of acamprosate/naltrexone. Sensitivity analyses in individuals with severe AUD and stratified subgroup analyses by different socioeconomic groups confirmed the robustness of the results.

Conclusion:

Results indicate a significant association between disulfiram and naltrexone monotherapy, as well as the combination of disulfiram with naltrexone or acamprosate, with a lower risk of alcohol‐related hospitalizations among individuals with AUD. Low prescription rates suggest that AUD medications are currently underutilized. Increasing the availability of these medications for individuals with AUD could help reduce alcohol‐related hospitalizations.

2025-07-01·JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH

Primary Care Visit Frequency Is Associated With Diagnosis But Not Pharmacotherapy Prescribing for Patients With Alcohol Use Disorder

Article

作者: Bishop, Ruth A ; Schreiner, Andrew ; Ward, Ralph ; Ball, Sarah ; McCauley, Jenna L ; Moran, William P

Abstract:

Primary care has been proposed as an ideal setting for the management of alcohol use disorder (AUD); however, there is limited research on the diagnosis and prescribing patterns of medications for alcohol use disorder (MAUD) within primary care. This retrospective study aims to determine whether primary care engagement is associated with the likelihood of an AUD diagnosis or prescription of MAUD. Analyzing administrative claims data from a statewide cohort of 10,138 Medicaid enrollees, only 5.9% of patients diagnosed with AUD were prescribed MAUD (including naltrexone, acamprosate, disulfiram, and topiramate). Patients with higher levels of primary care visit frequency were significantly more likely to carry an AUD diagnosis (p < .0001); however, primary care visit frequency was not associated with prescription of MAUD. This study highlights the underutilization of MAUD within primary care, and the need for research identifying successful strategies to address barriers to prescribing MAUD in this setting.

14

项与阿坎酸钙相关的新闻（医药）

2025-03-24

·Pharmaceutical Technology

Tempero secures $70m to advance addiction treatment candidate

The venture firm 8VC led the Series B funding round to support Tempero, which is developing treatments for substance use disorders. Credit: Ekaterina Chizhevskaya via Getty Images. Tempero Bio has raised $70m in Series B financing to advance its lead candidate TMP-301 through two clinical trials for alcohol use disorder (AUD) and cocaine use disorder (CUD). 8VC led the Series B round, with participation from Aditum Bio, Khosla Ventures, and other investors. The capital will support Phase III-enabling activities, preclinical studies for additional indications, and new formulations of TMP-301, as per the 24 March announcement. TMP-301 is a metabotropic glutamate receptor 5 (mGluR5)-negative allosteric modulator (NAM), which plays a role in central nervous system function. Tempero said that the candidate can prevent relapse by “targeting the underlying biology of addiction”. US-based Tempero has kicked off two clinical studies to support TMP-301’s development. This includes a Phase II trial evaluating TMP-301’s safety and efficacy in patients with AUD (NCT06648655), and a drug-drug interaction (DDI) study (NCT06648668) assessing the mGluR5-targeting candidate in individuals using cocaine. A full Phase II study in CUD is planned once the DDI study concludes. TMP-301 has shown promise in preclinical models of alcohol, cocaine, and opioid use disorder (OUD), and demonstrated safety and tolerability in Phase I studies involving over 80 healthy volunteers. Tempero was launched in 2020 by Aditum Bio, the investment firm founded by former Novartis executives Joe Jimenez and Mark Fishman, in partnership with pharmaceutical company Sosei Heptares. Sosei licenced TMP-301 to Tempero in return for an upfront payment and strategic equity stake in Tempero. Despite the public health burden of alcohol use disorder and cocaine use disorder, treatment options remain limited. Only three US Food and Drug Administration (FDA)-approved medications exist for alcohol use disorder, Antabuse (disulfiram), Revia/Vivitrol (naltrexone), and Campral (acamprosate). However, research from the US non-profit, the Federation of American Scientists (FAS), indicates they are only prescribed to around 2% of persons with AUD in the US. In the announcement accompanying the funding, Ricardo Dolmetsch, chief scientific officer of Tempero Bio said: “Substance use disorders affect 48 million Americans and contribute to more than 100,000 deaths per year. We urgently need more effective treatments to help patients and families with these diseases.” Beyond mGluR5 modulation, several other approaches are emerging. Glucagon- like receptor 1 agonists (GLP-1RAs), currently used for diabetes and weight loss, are being investigated for their potential to curb alcohol use and opioid addiction, signalling a shift in how substance use disorders may be treated in the future. mGluR5 modulation is also being explored in other indications. In January 2024, Switzerland-based Stalica raised $17.5m in Series B financing to fund clinical trials for its mGluR5-targeting candidate mavoglurant. Stalica signed an in-licencing agreement with Novartis to develop the drug as a treatment for substance use disorders and neurodevelopmental disorders (NDDs) in January 2023. The company is planning a Phase III trial for mavoglurant in patients with cocaine use disorder later in 2025.

临床2期临床1期临床3期临床结果

2025-02-12

·BioPharmaDive

New study offers hints of GLP-1 drugs’ potential in curbing alcohol cravings

Scientists believe GLP-1 drugs like Novo Nordisks Ozempic help people with obesity lose weight in part because they can help quell food cravings. Intriguing evidence that these drugs may also help people with alcohol use disorder limit drinking has motivated some doctors to try prescribing GLP-1s for those individuals, too.Controlled clinical trials are now beginning to catch up to clinical practice. A small Phase 2 study published Wednesday in the Journal of the American Medical Association Psychiatry gives some support for this hypothesis. Much of the evidence that has so far been published on alcohol use disorder has relied on animal research or patient records.The JAMA study, by comparison, randomly assigned people with obesity or who were overweight and also had alcohol use disorder to receive either placebo or a low dose of semaglutide, the active drug contained in Ozempic and Wegovy. Researchers then tested how much the drug changed drinking habits after about two months.Using a test in which trial volunteers were offered their preferred beverage to drink over two hours, the study found people who received either semaglutide or placebo drank less during the test at the end of the eight-week treatment period than they did at the beginning. Comparatively, though, study participants on semaglutide drank about 50% less than the people given placebo, as measured by breath alcohol concentration and grams of alcohol consumed.On a weekly basis, semaglutide was associated with a statistical reduction in drinks per drinking day, but not in drinks per calendar day. Treatment didnt seem to affect the number of drinking days versus abstinent days, but reduced participants reported cravings on a questionnaire.The trial, which involved just 48 people, isnt a conclusive verdict on semaglutides efficacy in this setting. And the results are far short of what would be needed for the Food and Drug Administration to formally approve the drugs use in alcohol use disorder. Still, the findings should provide some encouragement to Novo, which has a larger and longer-duration Phase 2 trial testing semaglutide, another obesity drug called cagrilintide and an experimental liver drug on people with alcohol use disorder and liver disease.Separately, Brigham and Womens Hospital in Boston is preparing to recruit volunteers to a trial of tirzepatide, a GLP-1 drug sold by Eli Lilly as Zepbound, in alcohol use disorder. Lillys CEO also said late last year that his company would begin exploring Zebpound as a treatment for alcohol and drug addiction.Reductions in consumption when considered at large scale could lead to improved health outcomes that are not currently appreciated, wrote the study researchers, led by Christian Hendershot, a public health professor at the University of Southern California.Such large-scale improvements in health outcomes were hinted at in a study assessing more than 200,000 patient records in Sweden. That research found people with alcohol or substance use disorders who took semaglutide or an older Novo GLP-1 drug called liraglutide were significantly less likely to have an alcohol or drug-related hospitalization.A larger type of data analysis that pools the results of clinical trials and other types of scientific research, called a meta-analysis, has cast some doubt on the hypothesis, however.The FDA has approved only three drugs to help reduce alcohol consumption: disulfiram in 1951, naltrexone in 1994 and acamprosate in 2004. Lundbeck gained European approval in 2013 for a drug called Selincro that reduced heavy drinking days among people with alcohol dependence. It was never approved in the U.S. for alcohol use disorders, although its active ingredient is approved as a nasal spray and injection to treat opioid overdoses.Semaglutide is approved as Wegovy for obesity and Ozempic for diabetes, while tirzepatide is marketed as Zepbound for obesity and Mounjaro for diabetes. '

临床2期上市批准临床结果

2024-11-15

·医学新视点

常用降糖、减肥药，还能用于戒酒？JAMA子刊：这两种药作用更佳

▎药明康德内容团队编辑喝酒伤身，这可不是一句空话。长期大量饮酒可导致酒精使用障碍的发生，患者对酒精使用的控制力削弱，导致生理依赖，耐受性增加以及心理、社会功能和身体的损害。相关研究显示，酒精使用障碍的终生患病率为9%，男性患病率是女性的48倍之多。心理社会支持治疗是酒精使用障碍治疗的基石，药物治疗数据比较有限，但整体也是有效的。既往动物实验发现，胰高血糖素样肽-1受体激动剂（GLP-1 RA）可减少酒精的使用，这提示GLP-1 RA或有潜力作为降低酒精危害的治疗方式。近日，JAMA Psychiatry发表一项研究，结果以简短报告的形式发布，表明GLP-1 RA中的司美格鲁肽和利拉鲁肽有助于减少酒精使用障碍患者的饮酒量，降低住院风险。截图来源：JAMA Psychiatry 这是一项观察性研究，纳入年龄16~64岁确诊为酒精使用障碍的患者22万多例，其中63.5%为男性，36.5%为女性，平均年龄40岁。中位随访8.8年间，其中6276例患者使用GLP-1 RA（主要为利拉鲁肽、艾塞那肽、度拉糖肽和司美格鲁肽），7.5万例患者接受酒精使用障碍药物（主要为disulfiram、acamprosate和纳曲酮）治疗。共有13万多（58.5%）的酒精使用障碍患者住院接受治疗。研究结果显示，接受GLP-1RA治疗的患者中，使用司美格鲁肽的患者风险最低，其中因酒精使用障碍住院风险降低了36%（aHR=0.64，95%CI：0.50~0.83），因任何物质使用障碍（指使用精神活性物质导致的任何精神障碍）住院风险降低了32%（aHR=0.68，95%CI：0.54~0.85）。其次是利拉鲁肽，其因酒精使用障碍住院风险降低了28%（aHR=0.72，95%CI：0.57~0.92），因任何物质使用障碍住院风险降低了22%（aHR=0.78，95%CI：0.64~0.97）。使用任何治疗酒精使用障碍的药物均可适当降低因酒精使用障碍住院风险和因任何物质使用障碍住院风险。 ▲使用不同药物的患者，因酒精使用障碍住院风险（A）和因任何物质使用障碍住院风险（B）差异（图片来源：参考文献[1]）此外，研究人员还发现，司美格鲁肽和利拉鲁肽可分别使因躯体症状住院风险降低22%（aHR=0.78，95%CI：0.68~0.90）和21%（aHR=0.79，95%CI：0.69~0.91），但并不能降低患者企图自杀的风险。研究第一作者兼通讯作者，来自东芬兰大学的Markku Lähteenvuo教授表示：“我们的研究结果表明，GLP-1RA不仅能够治疗糖尿病和肥胖，还可能有助于治疗酒精使用障碍和物质使用障碍，当然，这一发现仍需在随机对照试验中进一步验证”。点击文末“阅读原文/Read more”，即可访问JAMA Psychiatry官网阅读完整论文。推荐阅读欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。参考资料 [1]Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry. Published online November 13, 2024. doi:10.1001/jamapsychiatry.2024.3599 [2] 王岚,王冉,王学义.酒精使用障碍的危害及风险[J].神经疾病与精神卫生，2024，22（4）：229-233. [3]University of Eastern Finland. Obesity-fighting drugs may reduce alcohol consumption in individuals with alcohol use disorder.13-Nov-2024.https://www.eurekalert.org/news-releases/1064676 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医学新视点」微信公众号留言联系。如有其他合作需求，请联系wuxi_media@wuxiapptec.com 分享，点赞，在看，传递医学新知

临床结果AHA会议

100 项与阿坎酸钙相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02780	阿坎酸钙	N07BB03	DB00659

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
酗酒	美国	Forest Laboratories, Inc.	2004-07-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
暴食症	临床3期	美国	Forest Laboratories LLC	2007-04-01
精神分裂症	临床3期	美国	Forest Laboratories LLC	2006-09-01
创伤后应激障碍	临床2期	-	Synchroneuron, Inc.	2016-06-01
Tourette 综合征	临床2期	美国	Synchroneuron, Inc.	2015-04-01
迟发性运动障碍	临床2期	美国	Synchroneuron, Inc.	2014-02-01
甲基苯丙胺依赖	临床2期	美国	Forest Laboratories LLC	2007-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03818191 (CTgov)	临床4期	酒精使用障碍	288	Acamprosate (Acamprosate)	襯遞繭餘鑰膚繭遞鬱鬱 = 繭製齋鑰齋鹽餘艱選選夢鏇網襯廠膚淵選鹽艱 (餘鑰構衊構鏇襯築顧鑰, 觸廠醖糧衊糧範鹽選齋 ~ 選鏇齋範簾壓蓋願鑰觸) 更多	-	2024-12-17
				Placebo (Placebo)	襯遞繭餘鑰膚繭遞鬱鬱 = 廠顧膚觸鹽網壓繭觸構夢鏇網襯廠膚淵選鹽艱 (餘鑰構衊構鏇襯築顧鑰, 繭顧鏇遞糧廠醖衊艱網 ~ 鑰壓積觸淵艱餘顧壓鬱) 更多
DDW2024	N/A	酒精性肝疾病	-	Naltrexone	憲廠壓淵顧製選鑰艱範(淵積繭醖築遞廠艱齋獵) = the rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%) and none were stopped due to suspected DILI 製衊選構齋鏇夢積製艱 (醖蓋廠鬱遞廠淵膚糧顧 ) 更多	-	2024-05-20
				Acamprosate
DDW2024	N/A	酒精性肝疾病	-	Naltrexone	夢蓋觸憲觸範製鏇壓衊(構繭觸鑰獵觸淵夢醖鬱) = 願觸繭網製簾鬱襯夢餘築齋齋構窪積淵製築積 (醖憲構構選構製遞觸構 )	-	2024-05-20
				Acamprosate	夢蓋觸憲觸範製鏇壓衊(構繭觸鑰獵觸淵夢醖鬱) = 繭淵糧膚壓齋淵廠選範築齋齋構窪積淵製築積 (醖憲構構選構製遞觸構 )
NCT04287920 (CTgov)	临床2期	酒精使用障碍 \| 酒精性肝炎 \| 酒精性肝疾病	12	Acomprosate (Alcohol-related Liver Disease and AUD, MELD-NA Less Than 20)	積艱廠簾遞積蓋簾艱範 = 築範範鏇鹽鹽餘簾壓醖鹽網齋窪醖製鏇構鑰蓋 (獵鏇選衊齋製壓鬱膚範, 夢網膚觸築廠蓋顧製製 ~ 構獵糧選齋觸築網繭製) 更多	-	2022-12-20
				Acomprosate (Alcohol-related Liver Disease and AUD, MELD-NA More Than 20)	積艱廠簾遞積蓋簾艱範 = 願廠築憲遞獵窪壓衊製鹽網齋窪醖製鏇構鑰蓋 (獵鏇選衊齋製壓鬱膚範, 範憲獵顧鑰鹹鑰淵願餘 ~ 願餘淵餘願獵繭餘繭糧) 更多
EASL2021	N/A	酒精使用障碍 \| 纤维化	92	Acamprosate	鑰鏇窪鬱願窪艱餘壓衊(膚廠網鬱齋選製淵遞蓋) = 醖蓋網蓋壓獵齋餘艱壓壓糧遞遞淵顧鏇築積範 (鹽獵餘衊壓窪廠簾築鏇 )	积极	2021-06-23
				Baclofen	鑰鏇窪鬱願窪艱餘壓衊(膚廠網鬱齋選製淵遞蓋) = 夢餘積衊鏇繭廠糧簾繭壓糧遞遞淵顧鏇築積範 (鹽獵餘衊壓窪廠簾築鏇 )
NCT00466661 (CTgov)	临床4期	酗酒 \| 躁郁症 \| 躁郁症2型	33	Acamprosate (Acamprosate)	衊壓範齋襯窪憲憲鹽襯(憲膚廠觸製夢餘壓廠製) = 鹽壓膚廠鹽鹽衊繭積蓋網範齋夢蓋簾壓窪窪憲 (遞遞壓積簾範蓋遞網鹹, 製鹽選構艱築鏇構壓鹽 ~ 網齋淵鑰膚網襯獵鬱廠) 更多	-	2018-12-14
				Placebo (Placebo)	衊壓範齋襯窪憲憲鹽襯(憲膚廠觸製夢餘壓廠製) = 醖衊膚鬱衊構襯築窪獵網範齋夢蓋簾壓窪窪憲 (遞遞壓積簾範蓋遞網鹹, 膚範鹽鬱積獵鏇遞構淵 ~ 膚壓醖艱構醖遞膚襯襯) 更多
PXT-864 (EAN2018)	N/A	阿尔茨海默症	45	PXT-864 low dose	獵膚鏇鏇願蓋鏇憲艱淵(蓋壓餘範製淵窪醖淵選) = 窪齋糧選選鏇簾膚觸構鹽鏇壓壓鹽膚憲蓋衊窪 (壓觸範鹽積廠夢糧艱繭 )	积极	2018-06-14
SFN2016	N/A	酒精使用障碍	-	Acamprosate	艱淵願醖鏇選膚膚蓋齋(襯憲觸齋蓋鹹艱襯醖築) = 繭艱繭鹹餘範鑰襯膚淵壓積襯鹹廠簾蓋築艱鹽 (築衊壓窪願壓獵獵膚簾 )	-	2016-11-15
				Caffeine	艱淵願醖鏇選膚膚蓋齋(襯憲觸齋蓋鹹艱襯醖築) = 襯選願選壓醖觸顧醖範壓積襯鹹廠簾蓋築艱鹽 (築衊壓窪願壓獵獵膚簾 )
NCT00571922 (AcampMet, CTgov)	临床1/2期	甲基苯丙胺依赖	72	Acamprosate (Acamprosate)	獵繭憲鑰選構膚觸範觸(廠鏇積膚願衊選網窪範) = 廠鏇憲網鏇積蓋窪衊簾淵壓齋鹽顧鏇襯淵壓壓 (構選醖築壓獵遞夢願夢, 艱餘蓋鹽鏇網製糧鏇夢 ~ 網膚壓願製範膚鑰鹹鹹) 更多	-	2016-04-06
				placebo (Placebo)	獵繭憲鑰選構膚觸範觸(廠鏇積膚願衊選網窪範) = 範醖觸築齋網選蓋憲襯淵壓齋鹽顧鏇襯淵壓壓 (構選醖築壓獵遞夢願夢, 蓋淵糧餘鬱淵範繭顧選 ~ 艱衊網簾網鏇壓選餘構) 更多